SMS Pharmaceuticals Ltd (NSE:SMSPHARMA)

Q2 2026 SMS Pharmaceuticals Ltd Earnings Call Transcript

Nov 10, 2025 / 05:30 AM GMT

Release Date Price: ₹291.25 (-0.56%)

Transcript

Key Points

Positve

SMS Pharmaceuticals Ltd (BOM:532815) reported an 80% year-on-year growth in profit after tax, reaching 25.3 crores, marking the highest ever in a single quarter.
The company achieved a 23% year-on-year revenue growth in Q2 2026, supported by strong demand and market share gains across key APIs.
Backward integration projects have stabilized, significantly improving utilization levels and reducing dependency on external suppliers, particularly from China.
The company's R&D efforts have led to successful product launches and a strong presence in regulated markets, with plans to double R&D strength over the next two years.
SMS Pharmaceuticals Ltd (BOM:532815) maintains a diversified product mix across therapeutic areas, with no single therapeutic category accounting for more than 24% of revenue.

Negative

The company's CapEx plan of 280 crores is still in the early stages, with completion expected by November 2026, delaying potential revenue contributions until FY28.
The anti-diabetic segment has seen limited growth due to increased competition following patent expirations.
The company faces challenges in scaling up ibuprofen production to meet its target of 5,000 tons for FY26, currently averaging 350 tons per month.
Receivable days and working capital remain high, although the company states that receivables are below 120 days.
ARV segment growth is dependent on tender-based contracts, which can introduce variability in revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SMSP.NS - SMS Pharmaceuticals Ltd
Q2 2026 SMS Pharmaceuticals Ltd Earnings Call
Nov 11, 2025 / 05:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to SMS Pharmaceuticals Limited Q2 and H1F526 earnings conference call. This conference may contain forward-looking statements about the company which are based on beliefs, opinions, and expectations of the company as of the date of this time.

These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing then 0 on your touchstone phone. Please note that this conference

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.